---
schema_version: "secwatch.filing_event.v1"
accession: "0002023658-25-000094"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:55:59.992757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics Q2 2025: Cash $436.6M, net loss $27.4M; Phase 1/1b data show 54% ORR in HNSCC

## Summary
- Cash and equivalents $436.6M as of Jun 30, 2025, expected to fund operations into H1 2029.
- Q2 2025 net loss $27.4M vs $17.0M in Q2 2024; R&D expenses $24.8M (up $9M YoY) due to FORTIFI-HN01 trial.
- Updated Phase 1/1b data: 54% confirmed ORR, median DOR 21.7 months, median OS 21.3 months in 1L HPV-negative R/M HNSCC.
- Additional dose-cohort data (750mg weekly, 2000mg Q2W) expected Q4 2025–Q1 2026; enrollment ongoing in pivotal Phase 2/3.
- Pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa + pembrolizumab in 1L R/M HNSCC continues enrolling.

## SEC filing metadata
- accession: 0002023658-25-000094
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/0002023658-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/bcax-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002023658-25-000094
- JSON: https://secwatch.observer/filing/0002023658-25-000094.json
- Plain text: https://secwatch.observer/filing/0002023658-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.